NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis $2.31 -0.09 (-3.75%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.31 0.00 (0.00%) As of 10/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANEB alerts:Sign Up Key Stats Today's Range$2.26▼$2.4350-Day Range$2.01▼$3.1452-Week Range$0.80▼$3.42Volume35,759 shsAverage Volume123,951 shsMarket Capitalization$94.91 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments. The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S. Food and Drug Administration upon completion of these studies. Anebulo has established manufacturing and distribution strategies to support future commercialization, aiming to deliver a differentiated option for patients who require fast-acting, non-oral migraine relief. Founded in 2019 and headquartered in Campbell, California, Anebulo Pharmaceuticals brings together a team of industry veterans in drug delivery and neurology. By leveraging proprietary intranasal delivery technology, the company seeks to address unmet needs in migraine care and expand its development pipeline in related therapeutic areas.AI Generated. May Contain Errors. Read More Anebulo Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreANEB MarketRank™: Anebulo Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 467th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialAnebulo Pharmaceuticals has a consensus price target of $5.50, representing about 138.1% upside from its current price of $2.31.Amount of Analyst CoverageAnebulo Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Anebulo Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -8.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 8.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.65% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently decreased by 10.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.65% of the float of Anebulo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAnebulo Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Anebulo Pharmaceuticals has recently decreased by 10.75%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.52 News SentimentAnebulo Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Anebulo Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest12 people have searched for ANEB on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Anebulo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders80.60% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.Read more about Anebulo Pharmaceuticals' insider trading history. Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANEB Stock News HeadlinesAnebulo Pharmaceuticals’ Bold Move: Potential Risks of Going Private with Reverse Stock SplitOctober 2, 2025 | msn.comAnebulo Pharmaceuticals Advances Cannabis Toxicity TreatmentOctober 1, 2025 | msn.comGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century. | Stansberry Research (Ad)Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent UpdatesSeptember 29, 2025 | businesswire.comAnebulo begins Phase I trial of IV cannabis antidoteSeptember 26, 2025 | msn.comAnebulo Pharmaceuticals doses first subjects in selonabant studySeptember 25, 2025 | msn.comAnebulo Pharmaceuticals provides update on going private transactionSeptember 12, 2025 | msn.comAnebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic AlternativesSeptember 12, 2025 | businesswire.comSee More Headlines ANEB Stock Analysis - Frequently Asked Questions How have ANEB shares performed this year? Anebulo Pharmaceuticals' stock was trading at $1.68 at the beginning of 2025. Since then, ANEB shares have increased by 37.5% and is now trading at $2.31. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings data on Monday, September, 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at a price of $6.00-$8.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anebulo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anebulo Pharmaceuticals investors own include Hecla Mining (HL), Intra-Cellular Therapies (ITCI), Li Auto (LI), Norwegian Cruise Line (NCLH), PAR Technology (PAR), Transdigm Group (TDG) and Trade Desk (TTD). Company Calendar Last Earnings9/29/2025Today10/05/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANEB CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for Anebulo Pharmaceuticals$5.50 High Price Target$8.00 Low Price Target$3.00 Potential Upside/Downside+138.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-80.85% Return on Assets-76.33% Debt Debt-to-Equity RatioN/A Current Ratio24.51 Quick Ratio24.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book8.25Miscellaneous Outstanding Shares41,085,000Free Float7,970,000Market Cap$94.91 million OptionableNot Optionable Beta-0.89 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ANEB) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.